ea0029p1405 | Pituitary Clinical | ICEECE2012
Bertherat J
, Ludlam W
, Pivonello R
, Maldonado M
, Trovato A
, Hughes G
, Gu F
, Schopohl J
, Salgado L
Introduction: Rapid and sustained decreases in UFC and significant improvements in signs and symptoms were seen in a large, randomized, 12-month phase III study of pasireotide in Cushings disease. The safety profile of pasireotide was found to be similar to that of other somatostatin analogues, with the exception of hyperglycemia-related AEs (reported in 72.8% of patients). This abstract reports safety data from a 12-month extension to this phase III trial.<p class="...